Moreover, abatacept treatment have been shown to significantly reduce CD19+ B cell levels in the blood of remitted RA (DAS28-CRP < 2.6), but not in unremitted patients (Supplementary Fig. 2). This evidence concerns the gene CD19 and rheumatoid arthritis.